Format

Send to

Choose Destination
Curr Opin Microbiol. 1998 Oct;1(5):530-4.

New antibiotic discovery, novel screens, novel targets and impact of microbial genomics.

Author information

1
ZENECA Pharmaceuticals Cancer and Infection Research Department Mereside Alderley Park Macclesfield Cheshire SK10 4TG UK. Aileen. Allsop@alderley.zeneca.com.

Abstract

The clinical need for new classes of antibiotic continues to grow, as drug resistance erodes the efficacy of current therapies. Historically, most antibiotics were discovered by random screening campaigns, but over the past 20 years, this strategy has largely failed to deliver a sufficient range of chemical diversity to keep pace with changing clinical profiles. A more rational approach to drug hunting has been greatly potentiated by the availability of bacterial genomic information. The rapid progress in sequencing and analysis of these small, prokaryotic genomes has enabled the concomitant development of powerful new technologies that are already enhancing the potential utility of genomic information. The future promises versatile and precise tools to understand what makes a successful antibiotic and moreover the means to identify and evaluate novel classes of drug.

PMID:
10066524
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center